Document is current

Article History

Received: 23 October 2024

Accepted: 26 March 2025

First Online: 4 April 2025

Declarations

:

: Jacob J. Adashek serves on the advisory board of CureMatch Inc and as a consultant for datma. Jillian A. Moran has no disclosures to report. Dung T. Le serves as a consultant for Merck, Bristol Myers Squibb, Nouscom, G1 Therapeutics, Janssen, Regeneron, Tavotek Biotherapeutics, Catenion, Bayer, Sirtex, Tango Therapeutics, Endeavor Biosciences, and Merus and has received research funding from Merck, Bristol Myers Squibb, Curegenix, Nouscom, Medivir, and Abbvie. She has received speaking honoraria from Merck and is an inventor of licensed intellectual property related to technology for mismatch repair deficiency for diagnosis and therapy (WO2016077553 A1) from Johns Hopkins University. The terms of these arrangements are being managed by Johns Hopkins. Razelle Kurzrock has received research funding from Boehringer Ingelheim, Debiopharm, Foundation Medicine, Genentech, Grifols, Guardant, Incyte, Konica Minolta, Medimmune, Merck Serono, Omniseq, Pfizer, Sequenom, Takeda, and TopAlliance and from the NCI; as well as consultant and/or speaker fees and/or advisory board/consultant for Actuate Therapeutics, AstraZeneca, Bicara Therapeutics, Inc., Biological Dynamics, Caris, Datar Cancer Genetics, Daiichi, EISAI, EOM Pharmaceuticals, Iylon, LabCorp, Merck, NeoGenomics, Neomed, Pfizer, Precirix, Prosperdtx, Regeneron, Roche, TD2/Volastra, Turning Point Therapeutics, X-Biotech; has an equity interest in CureMatch Inc.; serves on the Board of CureMatch and CureMetrix, and is a co-founder of CureMatch.